1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

  • February 2014
  • -
  • GlobalData
  • -
  • 41 pages

Summary

Table of Contents

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Fanapt (iloperidone) is a D2/5-HT2A antagonist, but also has an increased activity at serotonin 5-HT7 receptors, which are believed to modulate striatal and cortical DA function. With enhanced antagonistic activity at a1 receptor sites and low activity on histamine H1 receptors, Fanapt has been associated with an issue of orthostatic hypotension (due to a1 blockade) rather than weight gain and sedation like other agents within its class.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fanapt including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fanapt for the top two countries from 2012 to 2022.
- Sales information covered for the US and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fanapt performance
- Obtain sales forecast for Fanapt from 2012-2022 in the top two countries (the US and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.